Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: a costeffectiveness analysis

Página do item simplificado
dc.creatorNayara Castelano Brito
dc.creatorTália Santana Machado Assis
dc.creatorAna Lúcia Teles Rabello
dc.creatorGlaucia Fernandes Cota
dc.date.accessioned2024-12-04T11:05:30Z
dc.date.accessioned2025-09-08T23:37:00Z
dc.date.available2024-12-04T11:05:30Z
dc.date.issued2019-12-05
dc.format.mimetypepdf
dc.identifier.doihtp://10.1371/journal.pntd.0007856
dc.identifier.issn1935-2735
dc.identifier.urihttps://hdl.handle.net/1843/78438
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPLOS Neglected Tropical Diseases
dc.rightsAcesso Aberto
dc.subjectLeishmaniose Cutânea
dc.subjectAntimoniato de Meglumina
dc.subjectSaúde Pública
dc.titleIntralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: a costeffectiveness analysis
dc.typeArtigo de periódico
local.citation.epage14
local.citation.issue12
local.citation.spage1
local.citation.volume13
local.description.resumoCutaneous leishmaniasis (LC) is a complex and variable disease in terms of epidemiology, aetiology, pathology and clinical characteristics. The mainstay of treatment is still pentavalent antimony (Sbv) compounds administered systemically, despite their recognized toxicity. The advantages of antimony intralesional (IL) infiltration are the use of lower doses of Sbv and, therefore, less toxic effects. The objective of this study was to estimate the cost-effectiveness ratio of intralesional meglumine antimoniate therapy (IL-MA) compared with endovenous meglumine antimoniate therapy (EV-MA) for the treatment of CL in the context of the Brazilian National Health System (SUS). An analytical decision model (decision tree) was developed using TreeAge Pro 2018 software. Data from the open-label, uncontrolled phase II clinical trial evaluating IL-MA were used as a reference for posology, efficacy, and adverse event rates (AE). The same premises for the intravenous approach (EV-MA) were extracted from systematic literature reviews. Macro and micro calculations of spending were included in the analysis. The IL-MA and EV-MA strategies had a total cost per patient cured of US$330.81 and US$494.16, respectively. The intralesional approach was dominant, meaning it was more economic and effective than was endovenous therapy. The incremental cost-effectiveness ratio showed that IL-MA could result in savings of US$864.37 for each additional patient cured, confirming that the IL-MA strategy is cost effective in the context of the Brazilian public health scenario.
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007856

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis- A cost-effectiveness analysis.pdf
Tamanho:
784.52 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG